Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q4 2024 ▲▼ | Q1 2025 ▲▼ | Change ▲▼ | Q4 2024 ▲▼ | Q1 2025 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Rezolute, Inc.(RZLT) | 1,318,967 | 1,318,967 | 0 | $6.46M | $3.83M | 75.28% | -$2.64M |
| SPDR Gold SharesGOLD SHS(GLD) | 1,169 | 1,298 | +129 | $283.1K | $374.1K | 7.36% | +$91.0K |
| Berkshire Hathaway Inc DelCL B | 1,133 | 467 | -666 | $513.6K | $248.8K | 4.90% | -$264.7K |
| Mind Medicine Mindmed Inc | 34,073 | 34,073 | 0 | $237.1K | $199.3K | 3.92% | -$37.8K |
| Bicara Therapeutics Inc | 10,941 | 10,941 | 0 | $190.6K | $142.6K | 2.81% | -$48.0K |
| Compass Therapeutics, Inc.(CMPX) | 43,465 | 43,465 | 0 | $63.0K | $82.6K | 1.63% | +$19.6K |
| Lexeo Therapeutics, Inc.(LXEO) | 17,851 | 17,851 | 0 | $117.5K | $61.9K | 1.22% | -$55.5K |
| Kyverna Therapeutics, Inc.(KYTX) | 22,981 | 22,981 | 0 | $86.0K | $44.4K | 0.87% | -$41.6K |
| Cardiff Oncology, Inc.(CRDF) | 13,287 | 13,287 | 0 | $57.7K | $41.7K | 0.82% | -$15.9K |
| Inhibikase Therapeutics, Inc.(IKT) | 16,393 | 16,393 | 0 | $53.3K | $35.9K | 0.71% | -$17.4K |
| Adicet Bio Inc | 17,488 | 17,488 | 0 | $16.8K | $13.2K | 0.26% | -$3.6K |
| Context Therapeutics Inc.(CNTX) | 18,403 | 18,403 | 0 | $19.3K | $11.3K | 0.22% | -$8.1K |
| Glycomimetics Inc | 203,578 | 0 | -203,578 | $50.9K | $0 | — | -$50.9K |
| State Street SPDR S&P 500 ETF TrustTR UNIT(SPY) | 2,823 | 0 | -2,823 | $1.65M | $0 | — | -$1.65M |
| Xeris Biopharma Holdings Inc | 2,015,157 | 0 | -2,015,157 | $6.83M | $0 | — | -$6.83M |